Our ambition is to change lives by changing the course of blood cancer.

Learn more

Latest Updates

Research & Development

Geron announces FDA acceptance of New Drug Application for imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS)

Learn more

Research & Development

Geron announces FDA Oncologic Drugs Advisory Committee (ODAC) votes in favor of clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk MDS

Research & Development

Geron announces fifty percent enrollment in the Phase 3 IMpactMF clinical trial for relapsed/refractory myelofibrosis (MF)

Events

View all

Investor Event

Watch the webcasts from Geron’s participation in two investor conferences in April

Geron’s Chairman and Chief Executive Officer, John Scarlett, M.D., hosted a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference and gave a corporate presentation at Stifel’s 2024 Virtual Targeted Oncology Days.

View webcasts here:

View now

Medical Congress

Geron data presentations at NCCN and HOPA 2024 Annual Conferences

Geron presented data at the National Comprehensive Cancer Network (NCCN) Annual Conference and the Hematology/Oncology Pharmacy Association Annual Conference (HOPA).

View the presentations here: